Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron presented nearly four-year follow-up data from the Phase 3 C-POST trial at ESMO 2026, showing an increasing overall survival benefit for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma. The reduction in risk of death improved from 14% at 24 months to 37% at 44 months of median follow-up, and this emerged despite 88% of placebo-arm patients crossing over to Libtayo after recurrence. Disease-free survival benefit was sustained regardless of baseline minimal residual disease status, with HRs of 0.45 in MRD-negative and 0.24 in MRD-positive patients.
Key figures
- Drug Name
- Libtayo (cemiplimab)
- Phase Of Trial
- Phase 3
- Enrollment
- 415
- Crossover rate
- 88% (61 of 69 placebo patients with recurrence)
- Dfs hr mrd negative
- 0.45 (95% CI 0.22-0.95)
- Dfs hr mrd positive
- 0.24 (95% CI 0.07-0.86)
- Median followup months
- 44
- Os risk of death reduction
- 37% (HR 0.63; 95% CI 0.36-1.11), up from 22% at 30 months and 14% at 24 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.